Published in Clin Immunol on April 22, 2016
Data on correlations between T cell subset frequencies and length of partial remission in type 1 diabetes. Data Brief (2016) 0.75
Memory T Cells in Type 1 Diabetes: the Devil is in the Detail. Curr Diab Rep (2017) 0.75
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol (2003) 38.57
Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity (2005) 23.00
An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol (2003) 19.16
B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity (2000) 15.44
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med (2005) 10.16
Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol (2005) 9.91
Foxp3-dependent programme of regulatory T-cell differentiation. Nature (2007) 9.48
TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med (2005) 6.87
Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol (2007) 6.80
Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev (2006) 6.08
In vivo instruction of suppressor commitment in naive T cells. J Exp Med (2004) 5.47
Regulatory T cell development in the absence of functional Foxp3. Nat Immunol (2007) 5.44
Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet (2011) 4.15
Resolution of lung inflammation by CD44. Science (2002) 4.09
Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat Genet (2009) 3.59
Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med (2012) 2.86
Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice. J Exp Med (2007) 2.86
High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J Exp Med (1994) 2.70
Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia (2010) 2.65
Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med (2013) 2.39
Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med (2015) 2.13
Soluble IL-2Rα facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma. Blood (2011) 1.75
New definition for the partial remission period in children and adolescents with type 1 diabetes. Diabetes Care (2009) 1.74
'The honeymoon phase' in children with type 1 diabetes mellitus: frequency, duration, and influential factors. Pediatr Diabetes (2006) 1.56
Cutting edge: high molecular weight hyaluronan promotes the suppressive effects of CD4+CD25+ regulatory T cells. J Immunol (2007) 1.38
Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4+CD25+ regulatory T cell function. J Immunol (2012) 1.31
CD44 costimulation promotes FoxP3+ regulatory T cell persistence and function via production of IL-2, IL-10, and TGF-beta. J Immunol (2009) 1.28
ECM components guide IL-10 producing regulatory T-cell (TR1) induction from effector memory T-cell precursors. Proc Natl Acad Sci U S A (2011) 1.17
Partial remission phase of diabetes in children younger than age 10 years. Arch Dis Child (1999) 1.16
CD44 (Pgp-1) inhibits CD3 and dexamethasone-induced apoptosis. Blood (1995) 1.15
Forms and functions of CD44. Immunology (1998) 1.15
Role of TGF-Beta in the induction of Foxp3 expression and T regulatory cell function. J Clin Immunol (2008) 1.14
T-cell reactivity to beta-cell membrane antigens associated with beta-cell destruction in IDDM. Diabetes (1995) 1.05
Recognition of posttranslationally modified GAD65 epitopes in subjects with type 1 diabetes. Diabetes (2014) 1.03
Multiple autoimmune-associated variants confer decreased IL-2R signaling in CD4+ CD25(hi) T cells of type 1 diabetic and multiple sclerosis patients. PLoS One (2013) 1.02
Interindividual variation in human T regulatory cells. Proc Natl Acad Sci U S A (2014) 1.01
The honeymoon phase: intersection of metabolism and immunology. Curr Opin Endocrinol Diabetes Obes (2009) 0.98
IL-2 therapy in type 1 diabetes: "Trials" and tribulations. Clin Immunol (2013) 0.97
Islet antigen specific IL-10+ immune responses but not CD4+CD25+FoxP3+ cells at diagnosis predict glycemic control in type 1 diabetes. Clin Immunol (2008) 0.96
Partial remission phase and metabolic control in type 1 diabetes mellitus in children and adolescents. J Pediatr Endocrinol Metab (2001) 0.94
Clinical application of regulatory T cells in type 1 diabetes. Pediatr Diabetes (2013) 0.93
Tr1 Cells, but Not Foxp3+ Regulatory T Cells, Suppress NLRP3 Inflammasome Activation via an IL-10-Dependent Mechanism. J Immunol (2015) 0.91
Two-year prospective evaluation of the factors affecting honeymoon frequency and duration in children with insulin dependent diabetes mellitus: the key-role of age at diagnosis. Diabetes Nutr Metab (2002) 0.91
Implication of CD44 in adhesion-mediated overproduction of TGF-beta and IL-1 in monocytes from patients with bone marrow fibrosis. Br J Haematol (1996) 0.88
Uncoupling of proliferation and cytokines from suppression within the CD4+CD25+Foxp3+ T-cell compartment in the 1st year of human type 1 diabetes. Diabetes (2011) 0.86
CD4(+)CD62L(+) central memory T cells can be converted to Foxp3(+) T cells. PLoS One (2013) 0.85
Assessment of CD4+ T cell responses to glutamic acid decarboxylase 65 using DQ8 tetramers reveals a pathogenic role of GAD65 121-140 and GAD65 250-266 in T1D development. PLoS One (2014) 0.85
β-cell-specific CD8 T cell phenotype in type 1 diabetes reflects chronic autoantigen exposure. Diabetes (2014) 0.84
Concentration and activity of the soluble form of the interleukin-7 receptor α in type 1 diabetes identifies an interplay between hyperglycemia and immune function. Diabetes (2013) 0.83
Factors influencing remission phase in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab (2002) 0.83
CD44 promotes progenitor homing into the thymus and T cell maturation. J Leukoc Biol (2008) 0.83
Plasma concentrations of soluble IL-2 receptor α (CD25) are increased in type 1 diabetes and associated with reduced C-peptide levels in young patients. Diabetologia (2013) 0.80
Immunointervention in type 1 (insulin-dependent) diabetes mellitus. Acta Clin Belg (1993) 0.76
Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes (2012) 3.11
The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. Pediatr Diabetes (2008) 2.60
Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies. Diabetes Care (2012) 1.45
Type 1 Diabetes TrialNet--an international collaborative clinical trials network. Ann N Y Acad Sci (2008) 1.44
Effect of rituximab on human in vivo antibody immune responses. J Allergy Clin Immunol (2011) 1.39
β cell death and dysfunction during type 1 diabetes development in at-risk individuals. J Clin Invest (2015) 1.31
The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients. Diabetes Care (2013) 1.23
Update on worldwide efforts to prevent type 1 diabetes. Ann N Y Acad Sci (2008) 1.19
Effectiveness of early intensive therapy on β-cell preservation in type 1 diabetes. Diabetes Care (2013) 1.15
The use of intermediate endpoints in the design of type 1 diabetes prevention trials. Diabetologia (2013) 1.09
The application of the diabetes prevention trial-type 1 risk score for identifying a preclinical state of type 1 diabetes. Diabetes Care (2012) 1.03
Electrochemiluminescence assays for insulin and glutamic acid decarboxylase autoantibodies improve prediction of type 1 diabetes risk. Diabetes Technol Ther (2015) 0.97
The effects of inpatient hybrid closed-loop therapy initiated within 1 week of type 1 diabetes diagnosis. Diabetes Technol Ther (2013) 0.92
Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report. Diabetes Care (2015) 0.91
Comparison of two insulin assays for first-phase insulin release in type 1 diabetes prediction and prevention studies. Clin Chim Acta (2011) 0.89
The implications of autoantibodies to a single islet antigen in relatives with normal glucose tolerance: development of other autoantibodies and progression to type 1 diabetes. Diabetologia (2015) 0.86
A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history. Diabetes Care (2014) 0.83
Heterogeneity in recent-onset type 1 diabetes - a clinical trial perspective. Diabetes Metab Res Rev (2015) 0.81
The relationship between BMI and insulin resistance and progression from single to multiple autoantibody positivity and type 1 diabetes among TrialNet Pathway to Prevention participants. Diabetologia (2016) 0.81
HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 Haplotype Protects Autoantibody-Positive Relatives From Type 1 Diabetes Throughout the Stages of Disease Progression. Diabetes (2016) 0.78
Prognostic Classification Factors Associated With Development of Multiple Autoantibodies, Dysglycemia, and Type 1 Diabetes-A Recursive Partitioning Analysis. Diabetes Care (2016) 0.78
Recommendations for the definition of clinical responder in insulin preservation studies. Diabetes (2014) 0.77
Excess BMI in Childhood: A Modifiable Risk Factor for Type 1 Diabetes Development? Diabetes Care (2017) 0.77
Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA1c, and Insulin Dose. Diabetes Care (2016) 0.76
The Receptor for Advanced Glycation Endproducts Drives T Cell Survival and Inflammation in Type 1 Diabetes Mellitus. J Immunol (2016) 0.75
Screening and Monitoring for Infectious Complications When Immunosuppressive Agents Are Studied in the Treatment of Autoimmune Disorders. J Pediatric Infect Dis Soc (2014) 0.75
Do Electrochemiluminescence Assays Improve Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects? Diabetes Care (2016) 0.75
A model-based approach to sample size estimation in recent onset type 1 diabetes. Diabetes Metab Res Rev (2016) 0.75
The shape of the glucose concentration curve during an oral glucose tolerance test predicts risk for type 1 diabetes. Diabetologia (2017) 0.75
The Role of Age and Excess Body Mass Index in Progression to Type 1 Diabetes in At-Risk Adults. J Clin Endocrinol Metab (2017) 0.75
Can non-HLA Single Nucleotide Polymorphisms Help Stratify Risk in TrialNet Relatives at Risk for Type 1 Diabetes? J Clin Endocrinol Metab (2017) 0.75
GAD vaccine reduces insulin loss in recently diagnosed type 1 diabetes: findings from a Bayesian meta-analysis. Diabetologia (2016) 0.75
Impact of age and antibody type on progression from single to multiple autoantibodies in type 1 diabetes relatives. J Clin Endocrinol Metab (2017) 0.75
Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet's Pathway to Prevention. Diabetes Care (2019) 0.75
Use of self-collected capillary blood samples for islet autoantibody screening in relatives: a feasibility and acceptability study. Diabet Med (2017) 0.75
Increasing ICA512 autoantibody titers predict development of abnormal oral glucose tolerance tests. Pediatr Diabetes (2017) 0.75